Aptorum Group Ltd Stock Price, News & Analysis

Aptorum Group Limited (Nasdaq: APM) has received a patent from the US Patent and Trademark Office for its Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics (RPIDD) technology, which offers a unique approach to DNA library preparation. This method significantly enhances the speed and simplicity of diagnostics for infectious diseases. Aptorum has an exclusive licensing agreement with Singapore's A*STAR institution for this technology. The company aims to expedite the clinical validation and pre-commercialization of RPIDD, which could transform clinical diagnostics and improve patient outcomes.

Aptorum Group (Nasdaq: APM) announced an interview with President Darren Lui on The RedChip Money Report® airing on Bloomberg TV on April 23 at 7 p.m. ET. The company is focused on developing drugs for oncology and infectious diseases and is advancing its drug discovery platforms. This includes co-developing rapid pathogen identification technology. The interview will reach approximately 73 million homes in the U.S., highlighting the company's efforts and developments in the biopharmaceutical sector.

Aptorum Group (Nasdaq: APM) announced that its drug candidate SACT-1 has received Orphan Drug Designation from the FDA for treating neuroblastoma. This designation supports Aptorum's plan to file an Investigational New Drug Application (IND) for a Phase 1b/2a clinical trial in 2022. Neuroblastoma, a serious pediatric cancer, has a 5-year survival rate of 40-50% for high-risk patients. The SACT-1 compound aims to enhance tumor cell death and can be used alongside standard chemotherapy, moving forward Aptorum's commitment to addressing unmet medical needs in oncology.

Aptorum Group (NASDAQ: APM) has announced the granting of its first patent for SACT-1, a repurposed drug aimed at treating various cancers, including neuroblastoma. This patent, numbered 11,166,962 B2, provides intellectual property protection for the drug's composition and its method of use in conjunction with other treatments. The company also revealed plans to pursue further patent protection and initiate Phase Ib/2a clinical trials for SACT-1 pending IND clearance. This milestone is crucial for protecting their investment and advancing their oncology pipeline.

Aptorum Group (APM) has completed Phase I clinical trials for two drugs: ALS-4 and SACT-1. ALS-4 targets infections from Staphylococcus aureus, including MRSA, while SACT-1 focuses on neuroblastoma. Both trials reported no serious adverse events and satisfactory safety data. Aptorum plans to submit IND applications to the US FDA for ALS-4's Phase II trial and SACT-1's Phase 1b/2a trial within the year. These milestones highlight Aptorum's commitment to addressing critical health needs, with both drugs aimed at combating serious unmet medical conditions.

Aptorum Group Limited (NASDAQ: APM) has initiated clinical validation of its rapid pathogen diagnostics technology (RPIDD) in Singapore, enrolling 12 patients with febrile neutropenia and sepsis. The RPIDD demonstrated analytical sensitivity of 100% and specificity of 90% in detecting pathogens, including Escherichia coli and Klebsiella pneumoniae. The technology aims to revolutionize infectious disease diagnostics, providing rapid results that could significantly reduce mortality rates. Pre-commercialization efforts are set to begin in 2022.

Aptorum Group Limited (NASDAQ: APM) has launched a new oncology and autoimmune discovery platform. This initiative focuses on developing treatments for significant unmet medical needs, particularly targeting non-small cell lung cancer (NSCLC) and autoimmune diseases like lupus and rheumatoid arthritis. The company aims to optimize first-in-class small molecule and PROTAC drug candidates, addressing mutations in NSCLC with a low five-year survival rate of 25%. Progression through clinical trials is anticipated as Aptorum leverages its drug discovery capabilities.

Aptorum Group Limited (Nasdaq: APM) announced results from its 2021 annual general meeting held on December 2, 2021, in Hong Kong. Shareholders re-elected all current directors and approved the re-appointment of Marcum Bernstein & Pinchuk LLP as independent auditors for 2021. Additionally, an amendment was made to the Articles of Association, allowing the board greater flexibility in setting record dates for shareholder meetings. The company focuses on developing therapies for oncological and infectious diseases, leveraging drug discovery platforms and partnerships for innovation.

Aptorum Group Limited (Nasdaq: APM) has announced its 2021 annual general meeting to be held on December 2, 2021, in Hong Kong. Shareholders of record as of October 6, 2021, are eligible to vote. The company also filed its annual report on Form 20-F with the SEC on April 19, 2021, which is accessible on its website. Aptorum focuses on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases. The meeting aims to engage shareholders in company governance and future strategies.